Dazodalibep
Horizon Therapeutics
['dazodalibep']
op0142 horizon dazodalibep (1500mg) anti-cd40l ph2 aliss trial in #sjogrens n=38/gr. 1ry analysis: deltaessdai day169 -6.3 (dif -2.2, significant). no sign diffs esspri, osdi, facitr. 5/6 essdai improvement in 25% patients also significant. 1 severe covid-19. #eular2023
Rheumatologist and Assistant Professor of Rheumatology at CAML. Sjögren Disease Coordinator for ERN-ReCONNET. MedEd, emotional learning & mental health advocate